Albuquerque’s Daisy Genomics Secures $2.5M in Seed Funding to Advance Next-Gen Sequencing for Precision Medicine
Daisy Genomics, an Albuquerque-based precision genomics company, has raised $2.5 million in seed funding to accelerate the development of its next-generation DNA and RNA sequencing platform. The funding represents a key step forward for the company as it works to bring a new approach to genomic and epigenetic analysis into clinical and research settings.
Founded in 2015 under the name Armonica Technologies, Daisy Genomics has spent nearly a decade developing a proprietary sequencing method designed to capture more biological information than conventional techniques. The company’s platform combines optical spectroscopy, nanofluidics, and custom chip technology to analyze DNA and RNA molecules without the extensive sample preparation typically required by existing sequencing methods. This approach is intended to enable faster analysis while preserving critical structural and epigenetic data that is often lost during standard sequencing workflows.
The seed round was led by Cottonwood Technology Fund, a New Mexico–based venture capital firm focused on deep technology and life sciences investments. Tramway Venture Partners, an early-stage venture firm that invests in healthcare and biotechnology companies in the Southwest, also participated in the round. The financing further included investment from Waves Capital Partners, expanding Daisy Genomics’ investor base as it prepares for the next phase of growth.
According to the company, the new capital will be used to advance its core technology, refine its spectroscopy chips, and move its sequencing platform closer to commercial readiness. Daisy Genomics also plans to expand partnerships with academic institutions and diagnostic organizations to validate its technology across a range of use cases. These include applications in precision medicine, oncology diagnostics, liquid biopsies, and epigenetic research, where capturing detailed molecular information is increasingly important.
Daisy Genomics is led by chief executive officer Emily Milsovic, who has emphasized the company’s goal of reshaping how genomic data is generated and interpreted. By enabling the direct analysis of DNA and RNA molecules with minimal processing, the company aims to reduce costs, shorten turnaround times, and improve the quality of data available to clinicians and researchers. The platform is designed to support more comprehensive insights into genetic variation and gene regulation, both of which are critical for personalized medicine.
Investors backing the round have highlighted the potential of Daisy Genomics’ technology to address long-standing limitations in sequencing. Existing methods often rely on amplification and chemical processing steps that can introduce bias or obscure meaningful biological signals. Daisy’s physics-based approach is intended to overcome these challenges, offering a differentiated solution in a competitive and rapidly evolving genomics market.
The funding comes amid strong momentum in the global genomics and precision medicine sectors, driven by growing demand for personalized healthcare, advances in molecular diagnostics, and the expanding use of genomic data in drug development. While large sequencing companies dominate much of the market, emerging startups like Daisy Genomics are attracting attention for their efforts to rethink foundational technologies and unlock new capabilities.
Daisy Genomics has chosen to remain headquartered in Albuquerque, reflecting a broader trend of biotechnology innovation emerging outside traditional coastal hubs. The company plans to continue building its team locally while leveraging the region’s research ecosystem and technical talent. Leadership has indicated that maintaining a strong presence in New Mexico is central to its long-term strategy as it scales operations and prepares for future funding rounds.
With its $2.5 million seed financing in place, Daisy Genomics is now positioned to reach key technical and commercial milestones. As it advances its sequencing platform toward broader validation and potential market entry, the company aims to play a meaningful role in the next wave of precision medicine innovation.
